Pemphigus Vulgaris Pipeline Analysis 2019 (H1)
- Published : Mar 2020
- Report Code : KSI061611434
- Pages : 90
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
Pemphigus Vulgaris (PV) Pipeline Analysis report covers 8 drugs currently in different phases of development. Pemphigus Vulgaris is a rare, autoimmune disorder characterized by painful blistering of the skin and mucous membranes. Organs generally affected by the disease are mouth, eyes, nose, throat, lungs, and genitals. Symptoms include the painful blisters on the skin or mouth along with the oozing, crusting, or peeling at the blister site. The disease is caused when the immune system mistakenly produces the antibodies against the proteins in healthy skin and mucous membranes. Therapy for Pemphigus Vulgaris includes treatment with corticosteroids or other immune-suppressing drugs.
The report provides Pemphigus Vulgaris (PV) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases, and journals among others have been taken into consideration while conducting secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Argenx BVBA, Alexion Pharmaceuticals, Inc and Novartis AG among others.
Scope:
· By Company
· By Phase
· By Molecule Type
· By Region
· By Route of Administration
* There may be changes in the final report as per data availability.
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1.Analysis by Company
1.2.2.Analysis by Phase
1.2.3.By Molecule Type
1.2.4.By region
2. Disease Overview
2.1.1.Introduction
2.1.2.Classification
2.1.3.Symptoms
2.1.4.Causes
2.1.5.Diagnoses
2.1.6.Treatment
2.1.7.Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1.Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
- Drug Name
- Generic Name
- Synonyms
- Company
- Collaborator
- Route of administration
- Target
- Mechanism of Action
- Technology
- Molecule type
- CAS Number
- Weight
- Chemical Formula
- IUPAC name
- ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2.Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Argenx BVBA
6.1.1.Introduction
6.1.2.Financials
6.1.3.Products and Services
6.1.4.SWOT
6.1.5.Recent Developments
6.2. Hanall Biopharma
6.2.1.Introduction
6.2.2.Financials
6.2.3.Products and Services
6.2.4.SWOT
6.3. Daewoong Co. Ltd.
6.3.1.Introduction
6.3.2.Financials
6.3.3.Products and Services
6.3.4.SWOT
6.3.5.Recent Developments
6.4. MorphoSys AG
6.4.1.Introduction
6.4.2.Financials
6.4.3.Products and Services
6.4.4.SWOT
6.4.5.Recent Developments
6.5. Novartis
6.5.1.Introduction
6.5.2.Financials
6.5.3.Products and Services
6.5.4.SWOT
6.5.5.Recent Developments
6.6. Principia Biopharma
6.6.1.Introduction
6.6.2.Financials
6.6.3.Products and Services
6.6.4.SWOT
6.6.5.Recent Developments
6.7. Alexion Pharmaceuticals, Inc
6.7.1.Introduction
6.7.2.Financials
6.7.3.Products and Services
6.7.4.SWOT
6.7.5.Recent Developments
6.8. Cabaletta Bio
6.8.1.Introduction
6.8.2.Financials
6.8.3.Products and Services
6.8.4.SWOT
6.8.5.Recent Developments
6.9. Rubius Therapeutics
6.9.1.Introduction
6.9.2.Financials
6.9.3.Products and Services
6.9.4.SWOT
6.9.5.Recent Developments
List of Tables
List of Figures
* There may be changes in the final report as per data availability.
Argenx BVBA
Hanall Biopharma
Daewoong Co. Ltd.
MorphoSys AG
Novartis
Principia Biopharma
Alexion Pharmaceuticals, Inc
Cabaletta Bio
Rubius Therapeutics
Related Reports
| Report Name | Published Month | Get Sample PDF |
|---|---|---|
| Connected Agriculture Market Size & Share: Report, 2021-2026 | Sep 2021 | |
| Pyrometer Market Size, Share & Trends: Industry Report, 2021-2026 | Jun 2021 | |
| Radiotherapy Market Size & Share: Industry Report, 2021-2026 | Jul 2021 | |
| Data Center Colocation Market Size & Share: Report, 2023 - 2028 | Jun 2023 | |
| Industrial Enzymes Market Size, Share & Trends: Repot, 2024-2029 | Mar 2024 |